Skip to main content

8 Result(s)

within Heike L. Pahl Remove this filter

and

  1. Article

    Open Access

    Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

    Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating disease‑related splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis of JAKo...

    Steffen Koschmieder, Susanne Isfort, Clemens Schulte… in Annals of Hematology (2023)

    Download PDF (1597 KB) View Article

  2. No Access

    Article

    Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice

    Acute myeloid leukemia (AML) carries a 10–100 fold lower mutational burden than other neoplastic entities. Mechanistic explanations for why a low number of mutations suffice to induce leukemogenesis are theref...

    Samuel Vorbach, Albert Gründer, Fengbiao Zhou, Christoph Koellerer… in Leukemia (2020)

  3. No Access

    Article

    Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms

    Tissue microarray (TMA) technique is an established high-throughput method to analyze multiple tissue specimens in parallel. However, in order to obtain reliable results from immunohistochemical analyses of T...

    Kathrin A. Limberger, Lioudmila Bogatyreva… in Histochemistry and Cell Biology (2017)

  4. No Access

    Chapter

    Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

    The establishment of imatinib as the standard therapy for CML marked the beginning of a new era of treatment. Due to occurring intolerance and resistance against the drug, develo** newer inhibitors was promo...

    Julius Wehrle, Heike L. Pahl, Nikolas von Bubnoff in Small Molecules in Oncology (2014)

  5. No Access

    Article

    Clinical and hematological presentation of children and adolescents with polycythemia vera

    Polycythemia vera (PV) in children and adolescents is very rare. Data on clinical and laboratory evaluations as well as on treatment modalities are sparse. Here, we report the long-term clinical course of a PV...

    Holger Cario, Mary Frances McMullin, Heike L. Pahl in Annals of Hematology (2009)

  6. No Access

    Article

    JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

    Nick Cross and colleagues report that the JAK2V617F somatic mutation that drives the development of chronic myeloproliferative neoplasms is associated with the presence of a specific inherited haplotype in JAK2.

    Amy V Jones, Andrew Chase, Richard T Silver, David Oscier, Katerina Zoi… in Nature Genetics (2009)

  7. No Access

    Protocol

    Assaying NF-KB and AP-1 DNA-Binding and Transcriptional Activity

    Nuclear factor-KB (NF-KB) and activator protein 1 (AP-1) are well-characterized ubiquitously expressed transcription factors that play important roles in the response to cellular stress situations. In unstimulate...

    Judith M. Mueller, Heike L. Pahl in Stress Response (2000)

  8. No Access

    Article

    Activators and target genes of Rel/NF-κB transcription factors

    The vertebrate transcription factor NF-κB is induced by over 150 different stimuli. Active NF-κB, in turn, participates in the control of transcription of over 150 target genes. Because a large variety of bact...

    Heike L Pahl in Oncogene (1999)